Target intelligence / Profile preview

Dachshund family transcription factor 2 (DACH2)

Target
DACH2
Molecular classification
Transcription factor
01

Overview

Dachshund family transcription factor 2 (DACH2) is a protein-coding gene and a vertebrate homolog of the Drosophila dachshund gene, encoding a transcription factor involved in cell fate determination during development of organs such as the eye, limb, and genital disc. The DACH2 protein contains two characteristic domains: an N-terminal DNA-binding domain and a C-terminal domain involved in protein-protein interactions. DACH2 is expressed in embryonic neural tissues, sensory organs, muscles, and developing limbs, indicating its broad developmental roles. In muscle, DACH2 acts as a negative regulator of myogenesis, modulating myogenin activity through mechanisms involving histone deacetylases. Expression and mutations of DACH2 have been implicated in premature ovarian failure and other congenital syndromes, and high DACH2 expression has been identified as an independent biomarker of poor prognosis in serous ovarian carcinoma, correlating with indicators of cell proliferation and DNA repair capacity. There are currently no drugs directly targeting DACH2, and its primary roles are developmental and regulatory rather than pharmacological.

Other names
Dachshund homolog 2DACH2Dach2dachshund family transcription factor 2
02

Biological functions

Regulation of organogenesisMyogenesis regulationTranscriptional regulationCell fate determinationNegative regulation of myogenin activityCo-repression of genes (e.g., via HDAC-dependent mechanisms)Potential regulation of DNA integrity and cell proliferation
03

Disease associations

Cancer (notably ovarian cancer)Premature ovarian failureCongenital syndromesPossibly chemotherapy resistance in tumors
04

Safety considerations

Potential challenges if modulating a developmental gene (pleiotropic/developmental consequences unknown)Correlation of high expression with poor prognosis in cancer, but no direct safety risks specific to therapeutic intervention reported
05

Biomarkers

Poor prognosis in ovarian (serous subtype) carcinomaHigh expression as indicator of chemotherapy resistance (preclinical association)

Beyond the preview

Go deeper on Dachshund family transcription factor 2 (DACH2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dachshund family transcription factor 2 (DACH2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call